LIVMARLI

Representative image: Rare liver disease research is gaining fresh attention as Mirum Pharmaceuticals reports new EASL 2026 data on volixibat, brelovitug, and LIVMARLI.

Pharma & Biotech

Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update

by Pallavi Madhiraju
June 1, 2026
0 Comments

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Read More

Representative image: Clinical researchers review liver disease imaging and trial data as Mirum Pharmaceuticals prepares to share VISTAS study results for volixibat in primary sclerosing cholangitis.

Pharma & Biotech

Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?

by Pallavi Madhiraju
May 4, 2026
0 Comments

Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.

Read More